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Abstract
Background: Patients with a diagnosis of schizophrenia are at an increased risk for developing metabolic syndrome,
which is associated with greater cardiovascular morbidity and mortality. Treatment with some commonly used
antipsychotic medications may increase the risk of developing metabolic syndrome. The aim of the study was to
evaluate the safety of lurasidone in patients who continued lurasidone or switched from risperidone to lurasidone. A
secondary aim was assessment of the effect of long-term lurasidone on the Positive and Negative Syndrome Scale
(PANSS).
Methods: The treatment sample in the current study consisted of clinically stable patients with schizophrenia
(N = 223) who had completed a 12-month, double-blind study of lurasidone vs. risperidone. In the current
extension study, all patients received 6 months of open-label treatment with lurasidone, either continuing
lurasidone assigned during the preceding double-blind trial, or switching from double-blind risperidone to
lurasidone. Safety and tolerability parameters included body weight, prolactin, and metabolic laboratory tests.
Results: Six months of OL treatment with lurasidone was generally well-tolerated, with a low incidence of parkinsonism
(4.5%) and akathisia (3.1%). Overall, few adverse events were rated as severe (4.9%), and discontinuation due to an adverse
event was low in the lurasidone continuation vs. risperidone switch groups (3.7% vs. 6.9%). In the lurasidone continuation
versus risperidone switch groups, change from OL baseline to 6-month endpoint (observed case) was observed in mean
body weight (− 0.6 vs. -2.6 kg), median total cholesterol (− 4.0 vs. + 4.5mg/dL), triglycerides (− 4.5 vs. -5.5mg/dL), glucose (0.0
vs. -3.0mg/dL) and prolactin (males, + 0.15 vs. -11.2 ng/mL; females, + 1.3 vs. -30.8 ng/mL). Improvement in PANSS total score
was maintained, from OL baseline to endpoint in the continuation vs. switch groups (+ 1.0 vs. -1.0; OC).
Conclusions: In this 6-month extension study, lurasidone treatment was generally well-tolerated and associated with
minimal effects on weight, metabolic parameters, and prolactin levels. Patients who switched from risperidone to lurasidone
experienced reductions in weight, metabolic parameters and prolactin levels commensurate with increases in these safety
parameters experienced during the previous 12months of treatment with risperidone.
Trial registration: ClinicalTrials.gov NCT00641745 (Date of Registration: March 24, 2008).
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Background
Non-response to treatment with an initial antipsychotic
occurs in at least 50% of patients with first episode
schizophrenia and increases as the illness becomes more
chronic and recurrent [1, 2]. The recommended next-
step treatment option in non-responders is switching to
an alternative antipsychotic [3, 4]. In addition to lack of
efficacy, problems with safety or tolerability frequently
necessitate switching antipsychotics [5].
Lurasidone is an atypical antipsychotic agent that has
demonstrated efficacy in short-term [6–9] and long-term
studies [10–12] of patients with schizophrenia, with a
safety profile indicating minimal effects on weight, meta-
bolic parameters, and prolactin [13, 14].
Previously, the effectiveness of switching patients with
schizophrenia or schizoaffective disorder to lurasidone
using 3 different dosing strategies has been evaluated
[15]. At the time of the switch, patients were in a non-
acute phase of their illness and were being treated with a
wide range of typical or atypical antipsychotics. This 6-
week study demonstrated that switching patients to lura-
sidone was associated with good efficacy and tolerability
and low rates of treatment failure (8%), regardless of
switching strategy (rapid or slow titration of lurasidone).
Initial improvement in weight and lipids was observed
after 6 weeks of treatment. In a 6-month, open-label
extension of this study, improvements in efficacy on lur-
asidone were maintained, with minimal long-term effects
on weight, metabolic parameters, and prolactin [16].
The effect on safety parameters of switching patients
with schizophrenia from olanzapine to lurasidone has
also been evaluated in a 6-month, open-label extension
study in which patients who completed 6 weeks of
double-blind, placebo-controlled treatment with olanza-
pine or lurasidone were switched to 6 months of open-
label lurasidone 40–120 mg/d [17]. At 6-month end-
point, switching from olanzapine to lurasidone resulted
in clinically meaningful (≥7%) reduction in weight in
29.0% of patients; and median reduction in lipid parame-
ters, including total cholesterol (− 15.0 mg/dL) and tri-
glycerides (− 28.0 mg/dL).
We now report results of an open-label extension study
in which patients with schizophrenia who completed a
double-blind, 12-month study of lurasidone versus risperi-
done [18] either continued lurasidone or switched from
risperidone to lurasidone for an additional 6 months of
open-label treatment. Notable safety results for lurasidone
vs. risperidone at endpoint of the initial double-blind
study included: mean reduction in weight (− 1.0 vs. + 1.5
kg) and waist circumference (− 0.6 vs. + 1.6 cm); smaller
mean increases in prolactin for females (+ 34.9 vs. 53.3 ng/
mL) but similar increases for males (13.5 vs. 14.1 ng/mL).
The primary objective of this study was to evaluate the
long-term safety, tolerability and overall effectiveness of




Detailed methods for the initial 12-month, double-blind
study have been previously reported [18]. Briefly, clinic-
ally stable outpatients, ages 18–75 years, with a diagnosis
of schizophrenia or schizoaffective disorder, were ran-
domly assigned in a 2:1 ratio to receive lurasidone (flex-
ibly dosed, 40–120 mg/d) or risperidone (flexibly dosed,
2–6 mg/d). Study completers were eligible to continue
into the current 6-month, open-label extension study
that was conducted from March 2009 to January 2011 at
sites in the United States (n = 40), South Africa (n = 7),
Argentina (n = 5), Chile (n = 5), Brazil (n = 4), Croatia
(n = 3), Thailand (n = 3), and Israel (n = 1). To maintain
the double-blind in the initial 12-month study, all
patients entering the current open-label study received
3 days of single-blind placebo washout followed by 7
days of lurasidone 80 mg/d. After 7 days, the lurasidone
dose could be titrated, based on the judgment of the in-
vestigator, in the range of 40–120mg/d.
The study was conducted in accordance with the Good
Clinical Practice Guidelines of the International Confer-
ence on Harmonisation and with the ethical principles
of the Declaration of Helsinki. The study was approved
by an institutional review board or independent ethics
committee at each study site, and all patients provided
written informed consent prior to initiation of study
procedures. No important changes in study design or
methodology were made after the study was initiated.
Assessments
Assessment visits occurred at baseline of the open-label
extension study and monthly thereafter. Adverse events
were based on patient self-report in response to an
open-ended question or were based on investigator
observation of changes in the patient during examin-
ation. Movement disorder symptoms were evaluated
with the Simpson-Angus Scale (SAS) [19], Barnes
Akathisia Rating Scale (BARS) [20], and Abnormal
Involuntary Movement Scale (AIMS) [21]. Safety assess-
ments included laboratory tests (chemistry and
hematology panels, lipid panel, glycosylated hemoglobin
[HbA1c], bone alkaline phosphatase, N-telopeptide,
osteocalcin, parathyroid hormone, prolactin, and testos-
terone), electrocardiograms (ECG), physical examina-
tions, and vital sign measurements. In a subset of
patients (at selected US sites), bone mineral density
assessments were performed (BMD, using dual-energy
x-ray absorptiometry [DXA]). T-scores were calculated
([patient’s BMD – mean BMD of sex-matched young
adults] / 1-SD of young adults), and standard criteria
Mattingly et al. BMC Psychiatry          (2020) 20:199 Page 2 of 13
were used to determine BMD category (normal vs.
osteopenia vs. osteoporosis) [22]. Ophthalmologic exam-
inations, including dilated funduscopic and slit lamp eye
examinations, were also performed.
Efficacy was assessed using the Positive and Negative
Syndrome Scale (PANSS) [23], Clinical Global Impres-
sion, Severity scale [21], and the Montgomery-Åsberg
Depression Rating Scale (MADRS) [24]. Training and
certification of raters at each investigational site on study
assessments was provided prior to initiation of the
double-blind study.
Statistical analysis
The primary safety analysis population consisted of all
patients who received at least one dose of lurasidone
during the 6-month open-label extension study. All
safety and efficacy outcomes were pre-specified and were
analyzed for the overall treatment sample, and for 2
patient subgroups: patients who received lurasidone in
the double-blind study, and patients who received risper-
idone in the double-blind study. Change scores were cal-
culated from double-blind baseline to open-label study
endpoint and from open-label baseline to open-label
study endpoint (month 6). Observed cases (OC) and last
observation carried forward (LOCF-endpoint) analyses
were performed.
Results
Patient disposition and study treatment
Of the 236 patients who completed the initial 12-month
double-blind study, 223 (94.5%) continued into the current
open-label extension study. Overall, 90.1% of patients com-
pleted at least 3months of open-label treatment with lurasi-
done, and 174/223 (78.0%) completed 6months of
treatment. Reasons for premature discontinuation included
adverse events (11/223; 4.9%), withdrew consent (11/223;
4.9%), lost to follow-up (10/223; 4.5%), insufficient clinical
response (8/223; 3.6%), and miscellaneous other reasons (9/
223; 4.0%). Figure 1 summarizes patient disposition for the
two pre-specified patient subgroups (based on double-blind
treatment assignment in the initial double-blind study.
Patient characteristics were similar at open-label base-
line in both the lurasidone continuation subgroup, and
the risperidone-to-lurasidone switch subgroup (Table 1).
The mean daily dose of lurasidone during open-label ex-
tension was 81.1 mg. Twenty-nine percent of patients
(n = 65) received at least one concomitant medication,
most commonly anxiolytics (22%), hypnotics/sedatives
(18%), antidepressants (15%), and anticholinergics (13%).
Safety
Adverse events
The most commonly reported adverse events were head-
ache (6.3%), psychotic disorder (5.4%), and parkinsonism
Fig. 1 Patient Disposition. LUR = lurasidone; RIS = risperidone; DB: double-blind; OLE: open-label extension
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(4.5%; Table 2), with minimal differences between the
lurasidone continuation versus risperidone switch groups.
For both groups combined, a total of 11 patients (4.9%)
experienced an adverse event rated as severe; and 10
patients (4.5%) experienced a serious adverse event, con-
sisting of schizophrenia (n = 3), psychotic disorder (n = 3),
ankle fracture (n = 1), lung carcinoma (n = 1), possible
seizure (n = 1), attempted suicide (n = 1; patient recovered
and completed the study), and a completed suicide (n = 1;
on open-label day 22 in a patient who had previously
received 12months of double-blind lurasidone, and who
was experiencing recurrent psychotic symptoms).
Extrapyramidal symptoms
In the combined patient groups, the proportion who
reported an extrapyramidal symptom (EPS)-related
adverse event during the extension study was 7.6%, and
the proportion with akathisia was 3.1%. EPS-related
adverse events reported in more than 1 patient were
parkinsonism (4.5%) and dystonia (1.3%). The incidence
of an EPS-related adverse event was similar in the lurasi-
done continuation versus risperidone switch groups
(Table 2). No patient discontinued due to an EPS-
related adverse event or akathisia. Mean change from
open-label baseline to study endpoint (LOCF) was 0.0
on the Simpson-Angus Scale, 0.0 on the Barnes Akathi-
sia Rating Scale global clinical assessment of akathisia,
and + 0.3 on the Abnormal Involuntary Movement Scale
total score. Body weight, BMI, waist circumference
Mean weight, BMI, and waist circumference were
reduced, from double-blind to open-label baseline, in
patients who received 12 months of treatment with lura-
sidone (− 1.1 kg, − 0.55 kg/m2, and − 0.4 cm, respect-
ively), and were increased in patients who received 12
months of treatment with risperidone (+ 2.4 kg, + 2.1 kg/
m2, + 2.8 cm, respectively; Table 3; Fig. 2).
Mean changes in mean weight, BMI, and waist
circumference at 6-month open-label endpoint (OC
analysis) were minimal in the lurasidone continuation
subgroup; in contrast, notable reductions were observed
in the subgroup that switched from risperidone to lurasi-
done (− 2.9 kg, − 1.0 kg/m2, − 1.6 cm, respectively; [OC]);
and the proportion of patients who experienced ≥7%
weight loss was 19.7%; Table 3).
Metabolic parameters
Median total cholesterol, triglycerides, and glucose were
reduced, from double-blind to open-label baseline, in
patients who received 12months of treatment with lurasi-
done (− 8.5mg/dL, − 13.0mg/dL, − 1.0mg/dL, respectively);
and in patients who received 12months of treatment with
risperidone, median triglycerides and glucose were minimally
increased (+ 1.0mg/dL, + 3.0mg/dL, respectively), while total
Table 1 Patient Characteristics (Open-Label Baseline, Safety
Population)
Characteristic LUR-LURa (N = 136) RIS-LURb (N = 87)
Male, n (%) 102 (75.0) 58 (66.7)
Age, mean (SD), y 43.9 (10.7) 42.8 (10.8)
Race, n (%)
White 50 (36.8) 39 (44.8)
Black 67 (49.3) 40 (46.0)
Asian 6 (4.4) 1 (1.1)
Other 13 (9.6) 7 (8.0)
Ethnicity, Hispanic/Latino, n (%) 36 (26.5) 25 (28.7)
Duration of illness, mean (SD), y 16.9 (10.7) 17.6 (11.9)
≥4 hospitalizations, n (%) 30 (22.1) 25 (28.8)
PANSS total score, mean (SD) 55.4 (13.6) 55.5 (11.2)
CGI-S score, mean (SD) 2.8 (0.8) 2.9 (0.8)
MADRS score, mean (SD) 5.1 (5.6) 4.3 (4.4)
CGI-S Clinical Global Impression-Severity Scale, LUR lurasidone, MADRS
Montgomery-Åsberg Depression Rating Scale, PANSS Positive and Negative
Syndrome Scale, RIS risperidone, SD standard deviation
a Patients who received lurasidone in both double-blind and
open-label studies
b Patients who received risperidone during the double-blind study and were
switched to lurasidone in the open-label study
Table 2 Adverse Events Reported in ≥2% of Patients During
Open-Label Treatment With Lurasidone




≥1 adverse event 80 (58.8) 51 (58.6)
Headache 7 (5.1) 7 (8.0)
Psychotic disorder 6 (4.4) 6 (6.9)
Parkinsonism 5 (3.7) 5 (5.7)
Anxiety 2 (1.5) 6 (6.9)
Blood creatine phosphokinase increased 5 (3.7) 3 (3.4)
Insomnia 3 (2.2) 5 (5.7)
Nasopharyngitis 5 (3.7) 3 (3.4)
Akathisia 5 (3.7) 2 (2.3)
Somnolence 5 (3.7) 2 (2.3)
Influenza 6 (4.4) 1 (1.1)
Nausea 3 (2.2) 3 (3.4)
Upper respiratory infection 6 (4.4) 0 (0)
Vomiting 3 (2.2) 3 (3.4)
Back pain 2 (1.5) 3 (3.4)
Decreased appetite 3 (2.2) 2 (2.3)
Weight decreased 4 (2.9) 1 (1.1)
LUR lurasidone, RIS risperidone
a Patients who received lurasidone in both double-blind and
open-label studies
b Patients who received risperidone during the double-blind study and were
switched to lurasidone in the open-label study
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Table 3 Change From Double-blind Baseline in Safety Parameters After 12-months of Treatment With Lurasidone or Risperidone,
Followed by 6-months of Open-label Treatment With Lurasidone (OC analysis)
Parameter LUR-LUR RIS-LUR
Weight, kg n = 109a n = 66a
DB Baseline mean (SD) 81.1 (18.25) 82.9 (18.65)
Mean change to OL Baseline (after 12-mo DB Tx) −1.1 + 2.4
Mean change from OL Baseline to Month 6-OL −0.6 −2.9
≥ 7% weight increase from DB Baseline, % 12.8 13.6
≥ 7% weight decrease from DB Baseline, % 28.4 18.2
≥ 7% weight increase from OL Baseline, % 1.8 3.0
≥ 7% weight decrease from OL Baseline, % 6.4 19.7
Body mass index, kg/m2 n = 109 n = 66
DB Baseline mean (SD) 27.7 (5.3) 28.8 (5.6)
Mean change to OL Baseline (after 12-mo DB Tx) −0.55 + 2.1
Mean change from OL Baseline to Month 6-OL −0.2 −1.0
Waist circumference, cm n = 104 n = 62
DB Baseline mean (SD) 93.8 (14.1) 97.5 (14.3)
Mean change to OL Baseline (after 12-mo DB Tx) −0.4 + 2.8
Mean change from OL Baseline to Month 6-OL −0.9 −1.6
Total cholesterol, mg/dL n = 108 n = 64
DB Baseline mean (SD) 196.4 (45.4) 188.0 (49.0)
Median change to OL Baseline (after 12-mo DB Tx) −8.5 −9.0
Median change from OL Baseline to Month 6-OL −4.0 + 4.5
Triglycerides, mg/dL n = 108 n = 64
DB Baseline mean (SD) 127.5 (57.7) 125.5 (88.8)
Median change to OL Baseline (after 12-mo DB Tx) −13.0 + 1.0
Median change from OL Baseline to Month 6-OL −4.5 −5.5
Glucose, mg/dL n = 105 n = 63
DB Baseline mean (SD) 95.1 (14.5) 94.6 (13.7)
Median change to OL Baseline (after 12-mo DB Tx) −1.0 + 3.0
Median change from OL Baseline to Month 6-OL 0.0 −3.0
Hemoglobin A1c, % n = 103 n = 63
DB Baseline mean (SD) 5.7 (0.4) 5.6 (0.4)
Median change to OL Baseline (after 12-mo DB Tx) 0.0 0.0
Median change from OL Baseline to Month 6-OL 0.0 0.0
Bone alkaline phosphatase, mcg/L n = 106 n = 61
DB Baseline mean (SD) 13.6 (5.2) 13.9 (4.3)
Median change to OL Baseline (after 12-mo DB Tx) −0.9 − 0.3
Median change from OL Baseline to Month 6-OL + 1.5 0
N-telopeptide (urine), nmol BCE/mmol creatinine n = 104 n = 62
DB Baseline mean (SD) 41.2 (120.3) 37.0 (35.8)
Median change to OL Baseline (after 12-mo DB Tx) + 1.5 −4.0
Median change from OL Baseline to Month 6-OL −1.0 + 0.5
Osteocalcin, ng/mL n = 104 n = 61
DB Baseline mean (SD) 5.25 (3.38) 5.70 (4.36)
Median change to OL Baseline (after 12-mo DB Tx) −0.85 −1.0
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cholesterol was reduced (− 9.0mg/dL; Table 3). Median
hemoglobin A1c levels were unchanged at double-blind
endpoint in both treatment groups.
In the lurasidone continuation group, minimal changes
were observed at 6-month open-label endpoint in median
total cholesterol, triglycerides, glucose, and hemoglobin
A1c (Table 3). In the risperidone switch group, small
reductions were observed in triglycerides and glucose
from open-label baseline to 6-month endpoint (− 5.5 mg/
dL, − 3.0 mg/dL, respectively; OC); while total cholesterol
increased (+ 4.5 mg/dL; Table 3). Median hemoglobin A1c
levels were unchanged from open-label baseline to 6-
month endpoint in both patient groups.
Prolactin
Median change in prolactin were notably different, from
double-blind to open-label baseline, after 12 months of
double-blind treatment with lurasidone and risperidone
in both men (− 0.6 ng/mL vs. + 12.8 ng/mL), and women
(− 0.75 ng/mL vs. + 35.2 ng/mL). In the lurasidone
continuation group, median change in prolactin was
minimal, from open-label baseline to 6-month endpoint
(OC analysis), for men (+ 0.15 ng/mL) and women (+
1.3 ng/mL); in the risperidone switch group notable
reductions were observed after 6 months of treatment
with lurasidone for men (− 11.2 ng/mL) and women (−
30.8 ng/mL; Table 3; Fig. 3a and b). No galactorrhea,
amenorrhea or gynecomastia were observed in patients
treated with open-label lurasidone.
Bone turnover markers and bone mineral density
As summarized in Table 3, minimal changes were
observed in markers of bone turnover (bone alkaline
phosphatase, osteocalcin, bone collagen equivalents, and
urinary N-telopeptide) for both lurasidone and risperidone
during 12months of double-blind treatment, and during
6months of open-label treatment with lurasidone.
In a subset of patients at US sites, bone mineral
density (BMD) was assessed by dual-energy x-ray ab-
sorptiometry [DXA]. Based on DXA assessments, no
loss of bone mineral density was observed during 6
months of open-label treatment with lurasidone in ei-
ther the lurasidone continuation group (n = 46) or the
risperidone switch group (n = 27). Median percent
change in BMD, from open-label baseline to 6-month
endpoint (OC) was + 0.4% in the lurasidone
Table 3 Change From Double-blind Baseline in Safety Parameters After 12-months of Treatment With Lurasidone or Risperidone,
Followed by 6-months of Open-label Treatment With Lurasidone (OC analysis) (Continued)
Parameter LUR-LUR RIS-LUR
Median change from OL Baseline to Month 6-OL 0 0
Parathyroid hormone, pg/mL n = 105 n = 61
DB Baseline mean (SD) 38.6 (17.4) 43.2 (27.8)
Median change to OL Baseline (after 12-mo DB Tx) 0 −2.0
Median change from OL Baseline to Month 6-OL + 2.0 + 4.0
Prolactin, ng/mL, males n = 84 n = 43
DB Baseline mean (SD) 7.7 (6.7) 10.2 (6.5)
Median change to OL Baseline (after 12-mo DB Tx) −0.6 + 12.8
Median change from OL Baseline to Month 6-OL + 0.15 −11.2
Prolactin, ng/mL, females n = 24 n = 21
DB Baseline mean (SD) 20.0 (24.7) 18.6 (40.8)
Median change to OL Baseline (after 12-mo DB Tx) −0.75 + 35.2
Median change from OL Baseline to Month 6-OL + 1.3 −30.8
Testosterone, total, ng/dL, males n = 84 n = 42
DB Baseline mean (SD) 498.1 (198.4) 481.3 (231.5)
Median change to OL Baseline (after 12-mo DB Tx) + 24.9 −103.0
Median change from OL Baseline to Month 6-OL −23.5 + 43.5
Testosterone, free, pg/mL, males n = 84 n = 40
DB Baseline mean (SD) 10.3 (5.5) 9.6 (6.2)
Median change to OL Baseline (after 12-mo DB Tx) −0.015 −1.405
Median change from OL Baseline to Month 6-OL −1.06 −0.095
BCE bone collagen equivalent, LUR lurasidone, RIS risperidone, DB double-blind, OL open-label, SD standard deviation, OC observed case
a Results presented are an observed case analysis of the number of patients available with test results at Month 18
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continuation group (n = 31) and 1.5% in the risperi-
done switch group (n = 13). For the combined treat-
ment groups, 4/44 patients (9.1%) experienced a gain,
from open-label baseline to 6-month endpoint, in
lumbar spine BMD resulting in a shift in BMD cat-
egory from osteoporosis to osteopenia, or from osteo-
penia to normal. A gain in lumbar spine BMD was
more common in patients switched from risperidone
to lurasidone (15.4% [2/13]) compared with patients
continuing lurasidone (6.5% [2/31]). No patient expe-
rienced a loss in BMD.
Electrocardiographic parameters
There were no clinically meaningful changes in mean
ECG parameters during 6months of open-label treatment
with lurasidone. One patient had a QTcF > 500msec at
the month 3 assessment, which represented a ≥ 60-msec
increase from open-label baseline; at the next assessment,
the patient had a QTcF < 450msec with a QTcF change
score < 60msec.
Physical examination and vital signs
There were no clinically meaningful changes in vital
signs (heart rate, systolic and diastolic blood pressure,
body temperature) during open-label treatment with
lurasidone.
In the subset of patients (n = 57) with an ophthalmo-
logic assessment that included dilated funduscopic and
slit lamp eye examinations, there were no clinically
significant treatment-emergent abnormalities in any
ophthalmologic parameter.
Efficacy
Patients (per protocol) were clinically stable at entry
into the double-blind study (mean baseline PANSS
total score of 65.1). At open-label baseline, after com-
pletion of 12 months of treatment with lurasidone or
risperidone, patients showed improvement in PANSS
total score (− 8.7 and − 8.3, respectively). Improvement in
PANSS total score was maintained during 6months of
treatment with lurasidone (mean [95%-CI] change from
OL baseline to LOCF-endpoint, + 1.0 [− 0.1, + 2.2]).
Improvement was maintained on the PANSS total score
in both the lurasidone continuation group (+ 1.0 [− 0.5, +
2.6]) and in the risperidone switch group (+ 1.0 [− 0.9, +
2.8]; LOCF-endpoint analysis; Fig. 4). Mean improvement
on the CGI-S was also maintained during 6months of
open-label treatment, both in the lurasidone continuation
group (0.0 [− 0.1, + 0.2]) and in the risperidone switch
group (0.0 [− 0.1, + 0.1]; LOCF-endpoint analysis of
change from open-label baseline).
At double-blind baseline, mean MADRS scores were
similar for patients randomized to lurasidone and risper-
idone (6.8 and 6.9, respectively). After completion of 12
months of double-blind treatment with lurasidone or
risperidone, mean change scores were − 1.7 and − 2.6,
respectively. Mean improvement on the CGI-S was
maintained during 6 months of open-label treatment,
both in the lurasidone continuation group (+ 0.2 [− 0.6,
+ 1.0]) and in the risperidone switch group (+ 1.0 [0.1,
2.0]; LOCF-endpoint analysis of change from open-label
baseline).
Discussion
Patients with schizophrenia who completed a previously
reported [18] 12-month, double-blind, flexible-dose
study of lurasidone versus risperidone, received 6
months of additional open-label lurasidone treatment,
with patients in the double-blind risperidone group
switching to lurasidone. At the end of the initial 12-
Fig. 2 Median Change in Weight From Double-Blind Baseline Through 6Months of Open-Label Treatment With Lurasidone, by Treatment Assignment in the
Double-Blind Study. LUR= lurasidone; RIS = risperidone. *Subgroup entering open-label extension; 6-month completer analysis: LUR-LUR, n=109; RIS-LUR,
n=66. †Patients in the RIS-LUR group received risperidone in the 12-month, double-blind study
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month, double-blind phase, treatment with risperidone
was associated with statistically significant increases
compared to lurasidone in weight, BMI, waist circumfer-
ence, prolactin levels, glucose, and insulin [18]. After 6
months of treatment in the current extension study,
patients who switched from risperidone to lurasidone
demonstrated consistent improvement in these safety
parameters, with reductions in weight, BMI, waist
circumference, glucose, and prolactin levels.
The patient group treated with lurasidone during the
initial 12-month study demonstrated consistent
improvement from double-blind baseline in weight,
BMI, glycemic indices, and metabolic parameters. Small
but consistent additional improvement was noted in
these parameters during the current 6 months of exten-
sion phase treatment with lurasidone.
The weight and metabolic results of the current study
are consistent with findings reported from previous lura-
sidone studies in which long-term treatment with lurasi-
done was associated with minimal effects on weight,
BMI, waist circumference, glycemic indices, and lipid
parameters [10–12, 16, 17, 25, 26].
The current results are also consistent with two
previously reported lurasidone switch studies. In the
first study patients who were treated for 6 weeks with
olanzapine showed clinically meaningful reductions in
weight, waist circumference, and selected metabolic parame-
ters after switching to 6months of treatment with lurasidone
a
b
Fig. 3 Median Change in Prolactin From Double-Blind Baseline Through 6Months of Open-Label Treatment With Lurasidone, by Treatment
Assignment in the Double-Blind Study. 3-A. Males. LUR = lurasidone; RIS = risperidone. *Subgroup entering open-label extension; 6-month completer
analysis: LUR-LUR, n = 102; RIS-LUR, n = 68. †Patients in the RIS-LUR group received risperidone in the 12-month, double-blind study. 3-B. Females.
LUR = lurasidone; RIS = risperidone. *Subgroup entering open-label extension; 6-month completer analysis: LUR-LUR, n = 34; RIS-LUR, n = 29. †Patients in
the RIS-LUR group received risperidone in the 12-month, double-blind study
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[17]. In the second study [15] patients (N= 240) with a diag-
nosis of schizophrenia who were stable on treatment with a
range of typical and atypical (e.g. olanzapine, quetiapine,
risperidone) antipsychotics were switched to lurasidone, 40–
120mg/d. After 6weeks of open-label treatment with lurasi-
done, improvement in weight and lipid parameters were
observed. In a 6-month, open-label extension of this study,
improvements in efficacy on lurasidone were maintained,
with minimal long-term effects on weight, metabolic param-
eters, and prolactin [17].
Among patients in the initial double-blind phase of
the current study, treatment with risperidone was asso-
ciated with notable increases in prolactin levels, with
commensurate reduction in prolactin in males (− 11.2
ng/mL) and females (− 30.8 ng/mL) following the
switch to lurasidone. Previous systematic reviews and
meta-analyses have ranked risperidone and its metabol-
ite paliperidone, in the group most likely to cause
hyperprolactinemia, while lurasidone is ranked in the
low-risk group [14, 27]. Prolactin-elevating effects of
antipsychotics does not appear to be well-correlated
with antagonist affinity for the dopamine D2 receptor.
Lurasidone has slightly higher D2 receptor affinity than
risperidone (Ki, 1.7 vs. 2.9 [28]. Instead, the brain/
plasma concentration ratio, and specifically pituitary D2
receptor occupancy, has been reported to be highly cor-
related with the hyperprolactinemic effects of atypical
antipsychotics in patients with schizophrenia [29, 30].
The mean daily dose of lurasidone used during the
current 6-month open-label study was 80 mg/d. In
the dose range of 40–120 mg/d utilized in the current
study, 6 months of treatment with lurasidone was
well-tolerated, with a low incidence of parkinsonism
(4.5%) and akathisia (3.1%), few adverse events rated
as severe (4.9%), and a low rate of discontinuation
due to adverse events in both the risperidone to lura-
sidone switch group (6.9%), and in the lurasidone
continuation group (3.7%).
Improvement in psychotic symptoms, as measured by
the PANSS total and CGI-S scores, that were observed
on both lurasidone and risperidone during the 12-month
double-blind phase were maintained after switching to
open-label lurasidone.
Notable study limitations include the open-label,
non-randomized design, and lack of an active control
group. In addition, the sample size in the risperidone
switch group that was available at the end of the ex-
tension study was relatively small (n = 66). While
these are common limitations of extension studies, in
this instance the limitations are partially mitigated by
the initial 12-month lead-in study, which provided a
randomized, double-blind comparison of lurasidone
and risperidone. We would further note that the com-
pletion rate was relatively high (79%) and was similar
for both the lurasidone continuation and risperidone
switch groups. Finally, it should be noted that enrol-
ment in the initial double-blind study was limited to
patients whose psychotic symptoms were clinically
stable, and therefore the efficacy results are not
generalizable to patients experiencing an acute exacer-
bation of schizophrenia.
Conclusion
Relatively little controlled data are available on whether ad-
verse safety effects associated with selected antipsychotics
can be reversed by switching medication. The current
Fig. 4 Mean PANSS Total Score From Double-Blind Baseline Through 6 Months of Open-Label Treatment With Lurasidone, by Treatment
Assignment in the Double-Blind Study. LUR = lurasidone; PANSS = Positive and Negative Syndrome Scale; RIS = risperidone. *Subgroup entering
open-label extension; 6-month completer analysis: LUR-LUR, n = 115; RIS-LUR, n = 71. †Patients in the RIS-LUR group received risperidone in the
12-month, double-blind study
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switch study extends the findings of the previous studies,
most of which concerned the weight and metabolic benefit
of switching away from olanzapine. The results of this 6-
month study suggest that Long-term treatment with lurasi-
done had minimal effects on body weight, waist circumfer-
ence, metabolic parameters, and prolactin levels. Patients
who switched from risperidone to lurasidone experienced
reductions in weight, waist circumference, metabolic pa-
rameters and prolactin levels commensurate with increases
in these safety parameters experienced during the previous
12months of treatment with risperidone.
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